amiodarone has been researched along with Lipidoses in 43 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Lipidoses: Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phospholipidosis is a metabolic disorder characterized by intracellular accumulation of phospholipids." | 1.48 | Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone. ( Boeckmans, J; De Boe, V; De Kock, J; Desmae, T; Natale, A; Rodrigues, RM; Rogiers, V; Vanhaecke, T, 2018) |
| "Drug-induced phospholipidosis (DIPL), in which phospholipids accumulate, is a known entity." | 1.46 | Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver. ( Ishida, Y; Kotake, Y; Ohta, S; Sanoh, S; Tamura, Y; Tateno, C; Yamachika, Y; Yoshizane, Y, 2017) |
| "To determine if amiodarone induces hepatic phospholipidosis (PLD) sufficient to detect changes in hepatobiliary transporter function as assessed by gadoxetate dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), rats were orally dosed with vehicle (1% methyl cellulose) or amiodarone (300 mg/kg/day) for 7 consecutive days." | 1.43 | Hepatic Phospholipidosis Is Associated with Altered Hepatobiliary Function as Assessed by Gadoxetate Dynamic Contrast-enhanced Magnetic Resonance Imaging. ( Goulbourne, CN; Jucker, BM; Lenhard, SC; Lev, M; Miller, RT; Peterson, RA; Webster, LO, 2016) |
| "Phospholipidosis (PLD) is characterized by an intracellular accumulation of phospholipids in lysosomes and concurrent development of concentric lamellar bodies." | 1.42 | Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment. ( Bocchini, N; Cristofori, P; Crivellente, F; Dacasto, M; Faustinelli, I; Ferraresso, S; Giantin, M, 2015) |
| "Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids." | 1.38 | In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012) |
| "Phospholipidosis (PLD), an abnormal accumulation of phospholipids within tissues, is observed during the preclinical testing of many pharmaceutical drugs." | 1.38 | Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats. ( Colatsky, T; Mans, D; Rosenzweig, BA; Shea, K; Stewart, S; Thompson, KL; Zhang, J, 2012) |
| "Phospholipidosis (PLD) is a topic of concern in drug development because it may be associated with toxicological consequences." | 1.37 | Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis. ( Atienzar, FA; Cossu-Leguille, C; Depelchin, O; Dhalluin, S; Gerets, HH; Hanon, E; Tilmant, K; Vasseur, P, 2011) |
| "Drug-induced phospholipidosis is marked by an excessive accumulation of phospholipids in lysosomes which can occur after exposure to cationic amphiphilic drugs." | 1.37 | High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. ( Havinga, J; Horbach, GJ; Ravesloot, WT; Schoonen, WG; van de Water, FM, 2011) |
| "Phospholipidosis is an adverse effect caused by numerous cationic amphiphilic drugs and can affect many cell types." | 1.36 | Predicting phospholipidosis using machine learning. ( Glen, RC; Lowe, R; Mitchell, JB, 2010) |
| " Amiodarone (30 mg/kg daily, a dosage corresponding to that used clinically) or vehicle was administered by gavage in 33 Wistar rats for two weeks." | 1.36 | Amiodarone attenuates apoptosis, but induces phospholipidosis in rat alveolar epithelial cells. ( Agelaki, MG; Kapatou, E; Kolettis, TM; Malamou-Mitsi, V; Pantos, C; Skyrlas, A, 2010) |
| "Phospholipidosis (PLD) is an accumulation of phospholipids in lysosome-derived multilamellar vesicles." | 1.35 | Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. ( Bhandari, N; Figueroa, DJ; Gerhold, DL; Lawrence, JW, 2008) |
| "Drug candidates under development by industry frequently show phospholipidosis as a side-effect in pre-clinical toxicity studies." | 1.35 | Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats. ( Horinouchi, A; Matsumoto, A; Miyamoto, S; Mori, I, 2009) |
| "Rats treated with gentamicin also had increased urinary levels of several phosphatidylinositol (PI), phosphatidylcholine (PC), and phosphatidylethanolamine (PE) species." | 1.34 | Biomarkers to monitor drug-induced phospholipidosis. ( Alden, C; Baronas, ET; Hsieh, FY; Lee, JW, 2007) |
| "Exposure to the toxic mineral dust silica has been shown to produce an acute inflammatory response in the lungs of both humans and laboratory animals." | 1.29 | Acute silica toxicity: attenuation by amiodarone-induced pulmonary phospholipidosis. ( Antonini, JM; McCloud, CM; Reasor, MJ, 1994) |
| "The presence of the phospholipidosis had no effect on the phagocytosis of heat-killed yeast cells, the induction of luminol-dependent chemiluminescence, or the spontaneous release of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), or spontaneous and LPS-stimulated release of IL-1 by alveolar macrophages in vitro." | 1.29 | Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. ( DiMatteo, M; Ima, A; Lemaire, I; McCloud, CM; Reasor, MJ; Schafer, R, 1996) |
| "Amiodarone is an antiarrhythmic drug that concentrates in the lungs and can cause pulmonary damage in humans." | 1.28 | Influence of a pre-existing phospholipidosis on the accumulation of amiodarone and desethylamiodarone in rat alveolar macrophages. ( Reasor, MJ, 1991) |
| "Amiodarone pulmonary toxicity represents an example of a life-threatening adverse drug reaction." | 1.27 | Amiodarone pulmonary toxicity: biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. ( Martin, WJ; Standing, JE, 1988) |
| "Typical phospholipidosis-like light and electron microscopic alterations were seen in the lung, their severity related to the extent of biochemical changes induced by amiodarone." | 1.27 | Amiodarone induced phospholipidosis. Biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone. ( Bertani, T; Bizzi, A; Boeri, R; Cini, M; Latini, R; Marchi, S; Pesenti, A; Riva, E; Tavbani, E; Veneroni, E, 1987) |
| "Treatment with amiodarone leads to an accumulation in the liver of this iodinated compound and hence an increase in the CT density of the liver." | 1.27 | Increased hepatic density and phospholipidosis due to amiodarone. ( Barker, ME; Boyer, TD; Goldberg, HI; Goldman, IS; Keung, E; Raper, SE; Winkler, ML, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (37.21) | 18.7374 |
| 1990's | 7 (16.28) | 18.2507 |
| 2000's | 6 (13.95) | 29.6817 |
| 2010's | 14 (32.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lowe, R | 1 |
| Glen, RC | 1 |
| Mitchell, JB | 1 |
| Fischer, H | 1 |
| Atzpodien, EA | 1 |
| Csato, M | 1 |
| Doessegger, L | 1 |
| Lenz, B | 1 |
| Schmitt, G | 1 |
| Singer, T | 1 |
| Dexter, A | 1 |
| Steven, RT | 1 |
| Patel, A | 1 |
| Dailey, LA | 1 |
| Taylor, AJ | 1 |
| Ball, D | 1 |
| Klapwijk, J | 1 |
| Forbes, B | 1 |
| Page, CP | 1 |
| Bunch, J | 1 |
| Sanoh, S | 1 |
| Yamachika, Y | 1 |
| Tamura, Y | 1 |
| Kotake, Y | 1 |
| Yoshizane, Y | 1 |
| Ishida, Y | 1 |
| Tateno, C | 1 |
| Ohta, S | 1 |
| Tomida, T | 1 |
| Ishimura, M | 1 |
| Iwaki, M | 1 |
| Natale, A | 1 |
| Boeckmans, J | 1 |
| Desmae, T | 1 |
| De Boe, V | 1 |
| De Kock, J | 1 |
| Vanhaecke, T | 1 |
| Rogiers, V | 1 |
| Rodrigues, RM | 1 |
| Yamagiwa, Y | 1 |
| Takei, Y | 1 |
| Koizumi, H | 1 |
| Nemoto, S | 1 |
| Kurata, M | 1 |
| Satoh, H | 1 |
| Bocchini, N | 1 |
| Giantin, M | 1 |
| Crivellente, F | 1 |
| Ferraresso, S | 1 |
| Faustinelli, I | 1 |
| Dacasto, M | 1 |
| Cristofori, P | 1 |
| Lenhard, SC | 1 |
| Lev, M | 1 |
| Webster, LO | 1 |
| Peterson, RA | 1 |
| Goulbourne, CN | 1 |
| Miller, RT | 1 |
| Jucker, BM | 1 |
| Bhandari, N | 1 |
| Figueroa, DJ | 1 |
| Lawrence, JW | 1 |
| Gerhold, DL | 1 |
| Ikeda, K | 1 |
| Hirayama, M | 1 |
| Hirota, Y | 1 |
| Asa, E | 1 |
| Seki, J | 1 |
| Tanaka, Y | 1 |
| Miyamoto, S | 1 |
| Matsumoto, A | 1 |
| Mori, I | 1 |
| Horinouchi, A | 1 |
| Kapatou, E | 1 |
| Skyrlas, A | 1 |
| Agelaki, MG | 1 |
| Pantos, C | 1 |
| Kolettis, TM | 1 |
| Malamou-Mitsi, V | 1 |
| Tilmant, K | 1 |
| Gerets, HH | 1 |
| Dhalluin, S | 1 |
| Hanon, E | 1 |
| Depelchin, O | 1 |
| Cossu-Leguille, C | 1 |
| Vasseur, P | 1 |
| Atienzar, FA | 1 |
| van de Water, FM | 1 |
| Havinga, J | 1 |
| Ravesloot, WT | 1 |
| Horbach, GJ | 1 |
| Schoonen, WG | 1 |
| Mesens, N | 1 |
| Desmidt, M | 1 |
| Verheyen, GR | 1 |
| Starckx, S | 1 |
| Damsch, S | 1 |
| De Vries, R | 1 |
| Verhemeldonck, M | 1 |
| Van Gompel, J | 1 |
| Lampo, A | 1 |
| Lammens, L | 1 |
| Thompson, KL | 1 |
| Zhang, J | 1 |
| Stewart, S | 1 |
| Rosenzweig, BA | 1 |
| Shea, K | 1 |
| Mans, D | 1 |
| Colatsky, T | 1 |
| Baronas, ET | 1 |
| Lee, JW | 1 |
| Alden, C | 1 |
| Hsieh, FY | 1 |
| Hasegawa, M | 1 |
| Takenaka, S | 1 |
| Kuwamura, M | 1 |
| Yamate, J | 1 |
| Tsuyama, S | 1 |
| Pintavorn, P | 1 |
| Larre, P | 1 |
| Coquet, M | 1 |
| Maupetit, J | 1 |
| Mazue, G | 1 |
| Vic, P | 2 |
| Gouy, D | 1 |
| Remandet, B | 1 |
| Lacheretz, F | 1 |
| Berthe, J | 1 |
| Barchewitz, G | 1 |
| Gagnol, JP | 1 |
| D'Amico, DJ | 1 |
| Kenyon, KR | 1 |
| Clemett, RS | 1 |
| MacKintosh, HT | 1 |
| Lüllmann-Rauch, R | 3 |
| Chew, E | 1 |
| Ghosh, M | 1 |
| McCulloch, C | 1 |
| Palmeri, S | 1 |
| Battisti, C | 1 |
| Malandrini, A | 1 |
| Federico, A | 1 |
| Antonini, JM | 1 |
| McCloud, CM | 3 |
| Reasor, MJ | 5 |
| Lee, P | 1 |
| Kirk, RG | 1 |
| Beard, TL | 1 |
| Ebert, DC | 1 |
| Kacew, S | 1 |
| Gardner, MF | 1 |
| Aldern, KA | 1 |
| Hostetler, KY | 1 |
| DiMatteo, M | 1 |
| Schafer, R | 1 |
| Ima, A | 1 |
| Lemaire, I | 1 |
| Bedrossian, CW | 1 |
| Warren, CJ | 1 |
| Ohar, J | 1 |
| Bhan, R | 1 |
| Dudognon, P | 1 |
| Hauw, JJ | 1 |
| de Baecque, C | 1 |
| Escourolle, R | 1 |
| Derrida, JP | 1 |
| Nick, J | 1 |
| Bockhardt, H | 2 |
| Drenckhahn, D | 2 |
| Martin, WJ | 1 |
| Standing, JE | 1 |
| Joshi, UM | 1 |
| Kodavanti, PR | 1 |
| Coudert, B | 1 |
| Dwyer, TM | 1 |
| Mehendale, HM | 2 |
| Michel, FB | 1 |
| Godard, P | 1 |
| Aubas, P | 1 |
| Riva, E | 1 |
| Marchi, S | 1 |
| Pesenti, A | 1 |
| Bizzi, A | 1 |
| Cini, M | 1 |
| Veneroni, E | 1 |
| Tavbani, E | 1 |
| Boeri, R | 1 |
| Bertani, T | 1 |
| Latini, R | 1 |
| Camus, P | 1 |
| Elving, LD | 1 |
| Hoefnagels, WH | 1 |
| Van Haelst, UJ | 1 |
| Griffioen, G | 1 |
| Janssens, AR | 1 |
| Ruiter, DJ | 1 |
| Goldman, IS | 1 |
| Winkler, ML | 1 |
| Raper, SE | 1 |
| Barker, ME | 1 |
| Keung, E | 1 |
| Goldberg, HI | 1 |
| Boyer, TD | 1 |
1 review available for amiodarone and Lipidoses
| Article | Year |
|---|---|
Experimentally induced lipidosis in rat retinal pigment epithelium. A brief review.
Topics: Amiodarone; Animals; Chloroquine; Chlorphentermine; Imipramine; Lipidoses; Microscopy, Electron; Per | 1981 |
42 other studies available for amiodarone and Lipidoses
| Article | Year |
|---|---|
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Bio | 2010 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse | 2012 |
Imaging drugs, metabolites and biomarkers in rodent lung: a DESI MS strategy for the evaluation of drug-induced lipidosis.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Biomarkers; Lipidoses; Lung; Male; Mass Spectrometry; R | 2019 |
Assessment of amiodarone-induced phospholipidosis in chimeric mice with a humanized liver.
Topics: Amiodarone; Animals; Chromatography, Liquid; Hepatocytes; Humans; Lipidoses; Liver; Mice; Phosphatid | 2017 |
A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis.
Topics: Amikacin; Amiodarone; Amitriptyline; Biological Assay; Chlorpromazine; Female; Hep G2 Cells; Humans; | 2017 |
Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone.
Topics: Amiodarone; Cell Differentiation; Cells, Cultured; Drug Evaluation, Preclinical; Drug-Related Side E | 2018 |
Pathological Features of Corneal Phospholipidosis in Juvenile White Rabbits Induced by Ocular Instillation of Chloroquine or Amiodarone.
Topics: Administration, Ophthalmic; Aging; Amiodarone; Animals; Chloroquine; Cornea; Disease Models, Animal; | 2019 |
Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment.
Topics: Amiodarone; Animals; Biomarkers; Cardiotoxicity; Drug Evaluation, Preclinical; Gene Ontology; Leukoc | 2015 |
Hepatic Phospholipidosis Is Associated with Altered Hepatobiliary Function as Assessed by Gadoxetate Dynamic Contrast-enhanced Magnetic Resonance Imaging.
Topics: Amiodarone; Animals; Biliary Tract; Gadolinium DTPA; Lipidoses; Liver; Magnetic Resonance Imaging; M | 2016 |
Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE.
Topics: Amiodarone; Animals; Cells, Cultured; Hepatocytes; Humans; Lipidoses; Macaca mulatta; Male; Phosphat | 2008 |
Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes.
Topics: Amiodarone; Animals; beta-N-Acetylhexosaminidases; Cells, Cultured; Endosomes; Kidney; Lipidoses; Ly | 2008 |
Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Topics: Amiodarone; Animal Testing Alternatives; Animals; Cytoplasmic Vesicles; Enzyme Inhibitors; Female; F | 2009 |
Amiodarone attenuates apoptosis, but induces phospholipidosis in rat alveolar epithelial cells.
Topics: Amiodarone; Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspase 8; Caspase Inhibit | 2010 |
Comparison of a genomic and a multiplex cell imaging approach for the detection of phospholipidosis.
Topics: Amiodarone; Animal Testing Alternatives; Animals; Anti-Arrhythmia Agents; Fluorescent Dyes; Foam Cel | 2011 |
High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis.
Topics: Amiodarone; Amitriptyline; Animals; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; Drug-Relate | 2011 |
Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP.
Topics: Amiodarone; Animals; Biomarkers; Cholesterol; Gene Expression Regulation; Glycerophospholipids; Lipi | 2012 |
Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats.
Topics: Acetaminophen; Amiodarone; Animals; Biomarkers; Chemical and Drug Induced Liver Injury; Histocytoche | 2012 |
Biomarkers to monitor drug-induced phospholipidosis.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Azithromycin; Biomarkers; Chroma | 2007 |
Urinary metabolic fingerprinting for amiodarone-induced phospholipidosis in rats using FT-ICR MS.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Biomarkers; Disease Models, Animal; Drug Evaluation, Pr | 2007 |
A wild zebra chase.
Topics: Amiodarone; Animals; Diagnosis, Differential; Fabry Disease; Female; Humans; Iatrogenic Disease; Kid | 2008 |
[Neuropathy induced by amiodarone].
Topics: Aged; Amiodarone; Benzofurans; Female; Humans; Lipidoses; Peripheral Nervous System Diseases | 1981 |
Recovery from amiodarone-induced lipidosis in laboratory animals: a toxicological study.
Topics: Amiodarone; Animals; Benzofurans; Cholesterol; Dogs; Foam Cells; Lipidoses; Lung; Lymph Nodes; Papio | 1984 |
Drug-induced lipidoses of the cornea and conjunctiva.
Topics: Amiodarone; Amodiaquine; Chloroquine; Conjunctival Diseases; Corneal Diseases; Fabry Disease; Female | 1981 |
Drug induced ocular lipoidosis.
Topics: Adolescent; Adult; Aged; Amiodarone; Benzofurans; Cataract; Color Vision Defects; Corneal Diseases; | 1982 |
Amiodarone-induced cornea verticillata.
Topics: Adult; Aged; Amiodarone; Benzofurans; Cornea; Corneal Diseases; Humans; Lipidoses; Microscopy, Elect | 1982 |
Amiodarone induced lipidosis similar to Niemann-Pick C disease. Biochemical and morphological study.
Topics: Amiodarone; Cells, Cultured; Cholesterol; Culture Media; Fibroblasts; Humans; Hydrolases; Kinetics; | 1995 |
Acute silica toxicity: attenuation by amiodarone-induced pulmonary phospholipidosis.
Topics: Acute Disease; Amiodarone; Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Lipidoses; | 1994 |
X-ray microanalysis of cultured alveolar macrophages with phospholipidosis.
Topics: Amiodarone; Animals; Cell Nucleus; Cells, Cultured; Chlorphentermine; Electron Probe Microanalysis; | 1993 |
Comparative evaluation of amiodarone-induced phospholipidosis and drug accumulation in Fischer-344 and Sprague-Dawley rats.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Kidney; Lipidoses; Liver; Macrophages, | 1996 |
Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Immunity, Innate; Interleukins; Lipidoses; Listeriosis; | 1996 |
Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Biomarkers; Biopsy; Bronchoalveo | 1997 |
[Amiodaron neuropathy: drug-induced lipidosis (author's transl)].
Topics: Aged; Amiodarone; Benzofurans; Humans; Lipidoses; Male; Peripheral Nervous System Diseases | 1979 |
Amiodarone-induced lipidosis-like alterations in ocular tissues of rats.
Topics: Amiodarone; Animals; Benzofurans; Cornea; Female; Keratitis; Lipidoses; Male; Rats; Retina | 1978 |
[Generalized lipidosis in rats following treatment with amiodarone and zimelidine].
Topics: Adrenal Glands; Allylamine; Amiodarone; Animals; Antidepressive Agents; Benzofurans; Cornea; Female; | 1978 |
Influence of a pre-existing phospholipidosis on the accumulation of amiodarone and desethylamiodarone in rat alveolar macrophages.
Topics: Amiodarone; Animals; Chlorphentermine; Lipidoses; Macrophages; Male; Phospholipids; Pulmonary Alveol | 1991 |
Amiodarone pulmonary toxicity: biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects.
Topics: Amiodarone; Bronchoalveolar Lavage Fluid; Humans; Lipidoses; Lung; Phospholipids | 1988 |
Types of interaction of amphiphilic drugs with phospholipid vesicles.
Topics: Amiodarone; Anilino Naphthalenesulfonates; Binding Sites; Chloramphenicol; Chloroquine; Chlorpromazi | 1988 |
[Lung, mirror of iatrogenic diseases. Example of amiodarone].
Topics: Adult; Aged; Amiodarone; Benzofurans; Female; Humans; Lipidoses; Lung Diseases; Male; Middle Aged; P | 1986 |
Amiodarone induced phospholipidosis. Biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone.
Topics: Amiodarone; Animals; Body Weight; Eating; Lipidoses; Lung; Lung Compliance; Male; Phospholipids; Pul | 1987 |
Pulmonary sequestration of amiodarone and desethylamiodarone.
Topics: Amiodarone; Animals; Benzofurans; Chromatography, High Pressure Liquid; In Vitro Techniques; Lipidos | 1986 |
Amiodarone hepatotoxicity.
Topics: Aged; Amiodarone; Chemical and Drug Induced Liver Injury; Female; Humans; Lipidoses; Liver; Male; Mi | 1986 |
Increased hepatic density and phospholipidosis due to amiodarone.
Topics: Aged; Amiodarone; Benzofurans; Biopsy; Humans; Lipidoses; Liver; Lysosomes; Male; Middle Aged; Phosp | 1985 |